Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. - Wikidata - awgldk - TriplyDB

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

http://www.wikidata.org/entity/Q40646153

about

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines Developing strategies in the immunotherapy of leukemias Trial watch: Dendritic cell-based anticancer therapy Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.Classification of current anticancer immunotherapies Cancer immunotherapy with mRNA-transfected dendritic cells.Messenger RNA-based vaccines.Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer?Antigenic targets for renal cell carcinoma immunotherapy.Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.RNA transfer and its use in dendritic cell-based immunotherapy.Immunotherapy in allogeneic hematopoietic stem cell transplantation--not just a case for effector cells.T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans.Antigen-specific cellular immunotherapy of leukemia.Tumor stroma-associated antigens for anti-cancer immunotherapy.Trial watch: Dendritic cell-based interventions for cancer therapy Current progress in the development of a cell-based vaccine for the immunotherapy of acute myeloid leukemia.Incomplete tumour control following DNA vaccination against rat gliomas expressing a model antigen.Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia.Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma Immune therapies.T-cell responses to survivin in cancer patients undergoing radiation therapy.Immunotherapy of chronic myeloid leukemia: present state and future prospects.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development.Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.Oral administration of Lactobacillus brevis KB290 to mice alleviates clinical symptoms following influenza virus infection.Trial watch: Dendritic cell-based interventions for cancer therapy.Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes.Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2.Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.

P2860

Q24804837-930C2E84-1A3C-4614-93DB-5C0736FD5A21 Q26996310-939E4961-FFCB-4D81-BF8B-E13D19FA00C9 Q27024047-88300404-05BB-4D54-9A7D-07472EA452AB Q28251858-3507F8C3-3DA5-4149-BD45-7845AA2438A4 Q28301522-CD7DC707-9382-4206-B58B-1F64F3E06474 Q33723063-D1B27B94-46B6-4512-B5CA-549E57608913 Q35149637-D0134AFB-DD42-44D8-9D7F-9B3B716AB0CD Q35826417-B10682D6-53D0-40C0-853F-30A3246506CB Q35842616-18CBB9A6-8BE1-41F7-BCEA-653C2E996A40 Q35905166-2D887F77-6FBF-441C-9040-0E077F47ED2D Q35925619-E0420365-FCBF-46F6-8C7B-CC0A63A782F5 Q36030919-104A7D79-03D5-440C-A415-9E79589EEFCA Q36065947-CA75B367-F68F-466A-A2BB-293AA367DA49 Q36090223-49AC6EEB-B70B-421E-9A98-897C36723216 Q36123756-CCB1DF9A-C90F-48BB-AD7C-60E18DB8E00A Q36124594-47D6F42A-4647-4E25-82D5-0B4CA586E169 Q36240201-73614BD9-1F44-4BE4-9834-C2CD76B0ED4B Q36284238-51EE2C6F-39C7-42A9-94F2-B94F42C2A9BA Q36388529-6F167AF5-BB8A-487D-8F0C-BC1D22C9A964 Q36445541-94EEF3D2-E80C-45F1-95BE-48F21C00D7C0 Q36503464-6DBD1653-A3EE-4CC8-844A-B3B20148451E Q36637647-27988591-2878-4046-A3A3-E64A258ED493 Q36948849-449EECA4-0C81-4079-B9A3-4854889A57DF Q36998232-5B908EB9-2F49-426A-BD53-A3FC7BCCC88E Q37357113-B16009D8-87E0-4E63-9A34-CF6EE9560030 Q37773256-98E6F335-9BC3-4AA0-B500-81C84C749DC3 Q37868974-9B21ACE4-89DF-4808-93C5-DC56AFC588CF Q38960752-AF483655-00FB-41B4-AD36-EA1C0888A0A4 Q39467521-3A1F9DAD-86B4-4FB6-BCE7-5C37C8DFF164 Q39792442-BC4D687F-748D-489A-AE26-EE3FEF488A8D Q40316208-DB041929-066A-4159-893A-19A66BD3B475 Q41503180-E3504B8E-6CFC-4977-8C7F-21EEA962736F Q42249690-C2386E93-6BA2-4A91-85DF-18912D1BAA18 Q42867339-D8C0FE48-C2E9-44BB-A5D3-DB2104168B71 Q45095151-09A4DF1B-B72C-459A-AA1A-8282A960FDF8 Q45881522-416B1F81-D373-4DE9-A2D7-EB514D7FBF40 Q45886109-9DB1FD90-D226-4BA8-8C43-A202EFCB8A55 Q48646241-AE2D11F4-C9FE-4795-9FE3-E4E8FF1E4617 Q50756622-09A1FE79-99FE-43B8-B9FF-87E4760ABCEC Q52569224-50A8AC09-3067-44BF-9411-12C8E2F513FE

P2860

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

http://www.wikidata.org/entity/Q40646153

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Generation of cytotoxic respon ...... A-transfected dendritic cells.

@en

type

label

Generation of cytotoxic respon ...... A-transfected dendritic cells.

@en

prefLabel

Generation of cytotoxic respon ...... A-transfected dendritic cells.

@en

P1433

Q40646153-41AA1CE9-AD02-4537-B6B1-BE2EC52B4CCD

P1476

Q40646153-BB00D58C-4332-45B3-A1F7-7B5C9955DBEF

P2093

Q40646153-0849F9E4-E8EB-4C7F-8666-5510919C9F62

Q40646153-0C402F42-716B-466A-8C82-6ED18EFA008C

Q40646153-329D0C3B-2B09-4C01-AB0D-A0FBA1A39E1A

Q40646153-676C33AC-66DB-4571-BAD7-9D138FC34BBF

Q40646153-685678A7-0F5A-405B-A1A0-A32E8CE680DE

Q40646153-6D429F45-18E2-48AF-B8BF-112F1602F4AE

Q40646153-6E6E3004-1996-4932-BD2B-9161B9581947

Q40646153-8B4A6D96-066D-44CD-9F99-CD1197C02C2C

Q40646153-DC908C66-FA03-4765-BF00-6215D5665F3F

Q40646153-F27B8529-79C0-479F-A506-849E63B2FCC7

P304

Q40646153-5A5FFB07-8A0D-4495-8B2A-89C4A5D0D0B2

P31

Q40646153-1A085E98-693B-4B39-ABA2-EC16CDBA67D6

P356

Q40646153-92750367-FC5A-4114-BC3E-14EB672F6F75

P407

Q40646153-6FA74555-31FC-4C33-AECD-94C35DDA6C85

P433

Q40646153-76BFA318-D9B1-4E76-A9F9-3D2D07785E56

P478

Q40646153-1C4567BA-962C-458A-A658-7D31F21BD9AF

P50

Q40646153-CFBA2DC7-C770-4356-B6CF-5F6D904DAE0B

P577

Q40646153-70FBB581-1D4A-4003-A56A-C5A166CB2F39

P5875

Q40646153-87BAB979-91FB-4BEF-9340-D7269C0A68F5

P698

Q40646153-AB6F3C17-2F7D-4651-9782-DCAC287AD282

P921

Q40646153-3D5BF021-AB68-4391-9276-6E0F98C71967

P356

JIMMUNOL.170.11.5391

P1433

Journal of Immunology

P1476

Generation of cytotoxic respon ...... NA-transfected dendritic cells

@en

P2093

Andreas Wagner

http://www.w3.org/2001/XMLSchema#string

Dieter Kabelitz

http://www.w3.org/2001/XMLSchema#string

Ilse Adamzik

http://www.w3.org/2001/XMLSchema#string

Marc Schmitz

http://www.w3.org/2001/XMLSchema#string

Matthias Marget

http://www.w3.org/2001/XMLSchema#string

Matthias Zeis

http://www.w3.org/2001/XMLSchema#string

Norbert Schmitz

http://www.w3.org/2001/XMLSchema#string

Peter Dreger

http://www.w3.org/2001/XMLSchema#string

Rita Kühl-Burmeister

http://www.w3.org/2001/XMLSchema#string

Sandra Siegel

http://www.w3.org/2001/XMLSchema#string

P304

5391-5397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.170.11.5391

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10750054

http://www.w3.org/2001/XMLSchema#string

P698

12759413

http://www.w3.org/2001/XMLSchema#string

P921